Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 16, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary Shares of 25 pence each.
- Purchase Date: November 16, 2012.
- Price Range: Highest price paid was 1,329 pence per share; lowest price paid was 1,315 pence per share.
- Treasury Holdings (Settled): 529,515,427 shares (9.72% of total issued share capital).
- Treasury Holdings (Including Unsettled): 530,140,427 shares (10.78% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,916,041,534 shares.
Material Changes
The primary material change reported is the reduction of outstanding share capital through the cancellation of 1,000,000 repurchased shares. Consequently, the percentage of shares held in Treasury increased to 10.78% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total cost of the 1,000,000 share repurchase based on the weighted average price between 1,315 and 1,329 pence.
- Confirm the impact of the 10.78% treasury holding on future earnings per share (EPS) calculations.
- Check subsequent filings for the settlement status of the 625,000 shares included in the "purchased but not yet settled" figure.
- Review the remaining authorization for share buybacks under the May 3, 2012 shareholder mandate.